BRCA1: the enigma of tissue-specific tumor development

被引:42
作者
Monteiro, ANA [1 ]
机构
[1] Cornell Univ, Weill Med Coll, Dept Cell & Dev Biol, New York, NY 10021 USA
[2] Strang Canc Prevent Canc, Oncol Mol Lab, New York, NY 10021 USA
关键词
D O I
10.1016/S0168-9525(03)00110-0
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Recent evidence indicates that BRCA1, a gene product associated with breast and ovarian cancer susceptibility, is an important component of the cellular response to DNA damage. Despite being expressed ubiquitously in adult tissues, germline mutations in BRCA1 predispose individuals to breast and ovarian tumors with only minor effects on the predisposition to cancer in other sites. The reason for this tissue specificity of BRCA1 carcinomas must be found if we are to understand fully why these tumors occur and to enable us to design efficient preventive and therapeutic regimens. Here I propose that tissue-specific rates of loss of heterozygosity in the BRCA1 locus could contribute to tissue specificity in tumor development.
引用
收藏
页码:312 / 315
页数:4
相关论文
共 33 条
[1]   Pathological studies of apoptosis in the normal breast [J].
Anderson, TJ .
ENDOCRINE-RELATED CANCER, 1999, 6 (01) :9-12
[2]   The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity [J].
Baer, R ;
Ludwig, T .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2002, 12 (01) :86-91
[3]  
Brodie S G, 2001, Trends Genet, V17, pS18, DOI 10.1016/S0168-9525(01)02451-9
[4]   EXPRESSION OF RECESSIVE ALLELES BY CHROMOSOMAL MECHANISMS IN RETINOBLASTOMA [J].
CAVENEE, WK ;
DRYJA, TP ;
PHILLIPS, RA ;
BENEDICT, WF ;
GODBOUT, R ;
GALLIE, BL ;
MURPHREE, AL ;
STRONG, LC ;
WHITE, RL .
NATURE, 1983, 305 (5937) :779-784
[5]   Distinct spectra of somatic mutations accumulated with age in mouse heart and small intestine [J].
Dollé, MET ;
Snyder, WK ;
Gossen, JA ;
Lohman, PHM ;
Vijg, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (15) :8403-8408
[6]   The BRCA1 suppressor hypothesis: An explanation for the tissue-specific tumor development in BRCA1 patients [J].
Elledge, SJ ;
Amon, A .
CANCER CELL, 2002, 1 (02) :129-132
[7]   BRCA1 inhibition of estrogen receptor signaling in transfected cells [J].
Fan, S ;
Wang, JA ;
Yuan, R ;
Ma, Y ;
Meng, Q ;
Erdos, MR ;
Pestell, RG ;
Yuan, F ;
Auborn, KJ ;
Goldberg, ID ;
Rosen, EM .
SCIENCE, 1999, 284 (5418) :1354-1356
[8]   The role of estrogen in mammary carcinogenesis [J].
Fishman, J ;
Osborne, MP ;
Telang, NT .
CANCER PREVENTION: FROM THE LABORATORY TO THE CLINIC: IMPLICATIONS OF GENETIC, MOLECULAR, AND PREVENTIVE RESEARCH, 1995, 768 :91-100
[9]   RISKS OF CANCER IN BRCA1-MUTATION CARRIERS [J].
FORD, D ;
EASTON, DF ;
BISHOP, DT ;
NAROD, SA ;
GOLDGAR, DE ;
HAITES, N ;
MILNER, B ;
ALLAN, L ;
PONDER, BAJ ;
PETO, J ;
SMITH, S ;
STRATTON, M ;
LENOIR, GM ;
FEUNTEUN, J ;
LYNCH, H ;
ARASON, A ;
BARKARDOTTIR, R ;
EGILSSON, V ;
BLACK, DM ;
KELSELL, D ;
SPURR, N ;
DEVILEE, P ;
CORNELISSE, CJ ;
VARSEN, H ;
BIRCH, JM ;
SKOLNICK, M ;
SANTIBANEZKOREF, MS ;
TEARE, D ;
STEEL, M ;
PORTER, D ;
COHEN, BB ;
CAROTHERS, A ;
SMYTH, E ;
WEBER, B ;
NEWBOLD, B ;
BOEHNKE, M ;
COLLINS, FS ;
CANNONALBRIGHT, LA ;
GOLDGAR, D .
LANCET, 1994, 343 (8899) :692-695
[10]   Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2:: Analysis of 10,000 individuals [J].
Frank, TS ;
Deffenbaugh, AM ;
Reid, JE ;
Hulick, M ;
Ward, BE ;
Lingenfelter, B ;
Gumpper, KL ;
Scholl, T ;
Tavtigian, SV ;
Pruss, DR ;
Critchfield, GC .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1480-1490